Response assessment using radiological methods

Critical Reviews in Oncology/Hematology

Volumn 30, Issue 1, 1999, Pages 45-62

  Gwyther, S J ^a  

^a EAST SURREY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BLEOMYCIN; CARBON 11; CISPLATIN; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

BREAST CANCER; CANCER; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; THORAX RADIOGRAPHY; TREATMENT OUTCOME; ULTRASOUND; UNITED KINGDOM;

HUMANS; NEOPLASMS;

EID: 0033052126     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00025-0     Document Type: Review

References (35)

1. Edwards D, Johnson NW, Cooper D, Warnakulasuriya KAAS Management of cancers of the head and neck in the United Kingdom: questionnaire survey of consultants. Br Med J. 315:1997;1589.
2. Rapidis AD, Angelopoulos AP, Langdon JD Ann R Coll Surg Engl. 62:1980;116-119.
3. MacVicar D, Husband JE Assessment of response following treatment for malignant disease. Br J Roentgenol. 70:1997;S41-S49.
4. Thames Cancer Registry. Cancer in South East England 1990. Sutton: Thames Cancer Registry, 1993.
5. Trends in cancer incidence and mortality in Scotland. CRC Factsheet 1998;26.1:1-6.
6. ISD Scotland 1998. Cancer Incidence Statistics Scotland: 1986-95. Edinburgh ISD.
7. Chu KC, Tarone RE, Kessler LG et al. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J NCI. 88(21):1996;1571-1579.
8. Slevin ML, Stubbs L, Plant HL et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J. 300:1990;1458-1460.
9. Miller AB, Hoogstraaten B, Staquet M et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
10. Gwyther SJ, Aapro MS, Hatty SR, et al. Results of independant review of 374 patients with non-small cell lung cancer treated with gemcitabine. 8th World Lung Conference, Dublin, 1997.
11. Gwyther SJ, Bolis G, Gore M, et al. Experience with independant radiological review during a topotecan trial in ovarian cancer. Ann Oncol 8:463-468.
12. Evaluation of response in solid tumours. Response Evaluation Criteria In Solid Tumour (RECIST) working group. Draft document, November 1997.
13. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol. 12:1994;2654-2666.
14. Trimble EL, Adams JD, Vena D et al. Paclitaxel for platinum refractory ovarian cancer: Results from the first 1000 patients registered to National Cancer Institute Treatment Referral Centre 9103. J Clin Oncol. 11:1993;2405-2410.
15. Notice for Guidance on Evaluation of Anticancer Medicinal Products in Man CPMP/205/95, Draft Guidelines. 19 June 1996.
16. Berland LL Slip-ring and conventional dynamic hepatic CT: contrast material and timing considerations. Radiology. 195:1995;1-8.
17. Oliver JH III, Baron RL, Federle MP et al. Hypervascular liver metastases: do unenhanced and hepatic arterial phase CT images affect tumor detection? Radiology. 205:1997;709-715.
18. Hollett MD, Jeffrey RB Jr, Nino-Murcia M et al. Dual phase helical CT of the liver: value of arterial phase scans in the detection of small (<1.5 cm) malignant hepatic neoplasms. Am J Roentgenol. 164:1995;879-884.
19. Werhli FW Principles of magnetic resonance. Stark D, Bradley WG Magnetic Resonance Imaging. 1988;3-23 Mosby, St. Louis.
20. Gwyther SJ Imaging in lung cancer. Lung Cancer Ther. 10:1995;301-305.
21. Hinson JA Jr, Perry MC Small cell lung cancer. CA Cancer J Clin. 43:1993;216-225.
22. Herman SJ Staging of bronchogenic carcinoma. World J Surg. 17:1993;694-699.
23. Webb Gatsonis C, Zerhouni EA et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology. 178:1991;705-713.
24. McLoud TC, Bourgouin PM, Greenberg RW et al. Bronchogenic carcinoma:analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 182:1992;319-323.
25. Rege SD, Hoh CK, Glaspy JA et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer. 72:1993;82-90.
26. Patz EF Jr, Lowe VJ, Hoffman JM et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2[F-18]-2-deoxy-D-glucose. Radiology. 191:1994;379-382.
27. Glaspy JA, Hawkins R, Hoh CK, Phelps ME Use of positron emission tomography in oncology. Oncology. 7:1993;41-50.
28. Coleman RE, Hoffman JM, Hanson MW et al. Clinical applications of PET for the evaluation of brain tumors. J Nuc Med. 32:1991;616.
29. Coleman RE, Sostman HD Functional and metabolic imaging. DeVita VTJ, Hellman S, Rosengerg SA Cancer. Principles and Practice of Oncology. 1997;673-682 Lippincott-Raven, Philadelphia, PA.
30. Robinson SP, Barton SJ, McSheedy PMJ, Griffiths JR Nuclear magnetic resonance spectroscopy of cancer. Br J Roentgenol. 70:1997;S60-S69.
31. Fulham MJ, Bizzi A, Dietz MJ et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology. 185:1992;675.
32. Negendank WG, Brown TR, Evelhoch JL et al. Proceedings of a National Cancer Institute workshop: MR spectroscopy and tumor cell biology. Radiology. 185:1992;875-883.
33. Negendank WG Studies in human tumors by MRS: a review. NMR Biomed. 5:1992;303-324.
34. Findlay MPN, Leach MO, Cunningham D et al. The non-invasive monitoring of low dose infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann Oncol. 4:1993;597-602.
35. Presant CA, Wolf W, Waluch V et al. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet. 343:1994;1184-1187.